Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
NCT02195869
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
45
Enrollment
INDUSTRY
Sponsor class
Conditions
Graft Versus Host Disease
Interventions
DRUG:
Ibrutinib
Sponsor
Pharmacyclics LLC.